Last reviewed · How we verify

Vonoprazan ODT-1 or ODT-2 without Water

Phathom Pharmaceuticals, Inc. · Phase 1 active Small molecule Quality 5/100

Vonoprazan ODT-1 or ODT-2 without Water is a Small molecule drug developed by Phathom Pharmaceuticals, Inc.. It is currently in Phase 1 development.

At a glance

Generic nameVonoprazan ODT-1 or ODT-2 without Water
SponsorPhathom Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vonoprazan ODT-1 or ODT-2 without Water

What is Vonoprazan ODT-1 or ODT-2 without Water?

Vonoprazan ODT-1 or ODT-2 without Water is a Small molecule drug developed by Phathom Pharmaceuticals, Inc..

Who makes Vonoprazan ODT-1 or ODT-2 without Water?

Vonoprazan ODT-1 or ODT-2 without Water is developed by Phathom Pharmaceuticals, Inc. (see full Phathom Pharmaceuticals, Inc. pipeline at /company/phathom-pharmaceuticals-inc).

What development phase is Vonoprazan ODT-1 or ODT-2 without Water in?

Vonoprazan ODT-1 or ODT-2 without Water is in Phase 1.

What are the side effects of Vonoprazan ODT-1 or ODT-2 without Water?

Common side effects of Vonoprazan ODT-1 or ODT-2 without Water include Constipation, Dizziness, Nausea, Vomiting, Dry skin, Erythema.

Related